Ranbaxy Generic Ceftin Closer To Launch With Appellate Court Ruling
Executive Summary
GlaxoSmithKline is not likely to win its Ceftin (cefuroxime axetil) patent infringement case against Ranbaxy, a D.C. federal appellate court said in an Aug. 20 ruling.